⌕
Telix Pharmaceuticals · TLX · Nasdaq
Tenet 41 · Weak
Compare
$8.86−0.73%At closeTenet 41 · Weak
$8.86−0.07 (−0.73%)
At close: Nov 17, 2026, 4:00 PM ET· Nasdaq · USD

Telix Pharmaceuticals (TLX) Income Statement

Is this a real, growing, cash-generative business, or a story propped up by accounting?

Sources Company filings FilingsHow we compute thisNot investment advice

6 figures withheld by our checks. Each blank figure names its reason.

Business engineGrowing fast: revenue compounds ~96.1%/yr (FY22→FY25), net margin −1.9%. Worth your attention in FY25: Capex step-up ($43.8M). Visible in the receipts below.
The four lines that matter · FY22–FY25
Revenue ($M)▲55.4%
821.4
FY22→FY25CAGR +96.1%/yr
Net income ($M)—
−15.5
FY22→FY25CAGR —
Free cash flow ($M)—
−61.1
no value for 1 of 4 yearsCAGR —
Diluted EPS—
—
no FY25 valueCAGR —
What the receipts whisper · what a headline number hides
Capex step-up
$43.8M

▲97% YoY in FY25, largest jump in this window; watch free-cash-flow conversion.

What the income statement says · FY22–FY25
Where every revenue dollar goes · FY25 ($M)821.4Revenue−462.8COGS−171.2R&D−95.8SG&A−5.3Op income−10.2Tax & other−15.5Net income

-2¢ of every revenue dollar becomes profit. The biggest cost lever is COGS.

Margin trend · direction beats level Operating Net
20151050%sector median net margin ~3%FY22FY25

Net margin -1.9% is below the sector median. This filer reports no gross profit line, so that margin is not drawn.

The receipt · income statement · FY22–FY25 USD thousands except per-share & ratios · hover a line for its definition
USD thousands except per-share & ratios
Line itemFY25 †FY25FY24FY23FY22YoYCAGR 22→25
Revenue & profitability
Revenue
821,355.0821,355.0528,616.0309,822.0108,945.3▲55.4%+96.1%
Cost of revenue
462,817.0462,817.0221,500.0138,781.044,348.2▲108.9%+118.5%
Gross profit
——A336,163.0209,533.064,597.1——
Research & development
171,249.0171,249.0127,930.085,315.054,907.5▲33.9%+46.1%
Selling, general & admin
95,789.095,789.085,318.049,668.032,089.7▲12.3%+44.0%
Total operating expenses
363,804.0363,804.0269,201.0168,447.0111,708.2▲35.1%+48.2%
Operating incomefeeds ROC rank
−5,266.0−5,266.037,915.02,594.0−62,558.4——
Other income, net
−1,242.0−1,242.0−3,287.0−612.0−4,553.9——
Pretax income
−6,508.0−6,508.034,628.01,982.0−67,112.3——
Income tax
1,859.01,859.04,230.0−1,614.03,713.5▼56.1%−20.6%
Net incomePiotroski ROA ✕feeds Buffett Quality owner earnings
−15,492.0−15,492.064,083.07,804.0−70,825.8——
Per share
Diluted EPSbuyback-sensitive
————−22.80——
Diluted shares (mn)
338.78338.78334.72——▲1.2%—
Margins
Gross margin
——B—B—B—B——
Operating margin
−0.6%−0.6%7.2%0.8%−57.4%▼7.8pp+56.8pp
Net margin36th pct in Healthcare
−1.9%−1.9%12.1%2.5%−65.0%▼14.0pp+63.1pp
† FY25 = fiscal 2025, through 2025-12-31; the trailing year is not available.A Withheld: our recalculation of this figure from its inputs did not match the reported value.B Withheld by our checks.
CSV export is on Premium.Premium · $119/yr · 7-day trial · cancel anytimeUnlock with Premium →
Annual report filed 2026-02-20 · view filings on SEC EDGAR ↗ · reported currency USD · as-filed figures may be later restated.
Statements normalized in our fundamentals DB · Not investment advice.

What was Telix Pharmaceuticals' revenue last fiscal year?

Telix Pharmaceuticals reported revenue of $821.4M in fiscal 2025, up 55.4% from fiscal 2024.

What was Telix Pharmaceuticals' net income?

Telix Pharmaceuticals reported net income of −$15.5M in fiscal 2025, a net margin of −1.9%.

Annual and quarterly statements as filed, normalized into one comparable shape · Not investment advice.

Install Tenet on your phone

Tenet home pageMethodology© 2026 Tenet Investing Inc.

Data from Intrinio and Financial Modeling Prep.